Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Trial details
- Registry ID
- NCT07562152
- Phase
- Phase 3
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic AdenocarcinomaNCT07562152 | Immuneering Corporation | Phase 3 | Recruiting | 2028-06Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |